<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02848196</url>
  </required_header>
  <id_info>
    <org_study_id>1580</org_study_id>
    <nct_id>NCT02848196</nct_id>
  </id_info>
  <brief_title>An Image-guided SBRT for Adrenal Gland Metastasis in Oligometastatic Patients</brief_title>
  <official_title>A Phase II Trial of Image-guided Stereotactic Body Radiation Therapy (SBRT) for Adrenal Gland Metastasis in Oligometastatic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istituto Clinico Humanitas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istituto Clinico Humanitas</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is designed to to assess the efficacy of ablative SBRT delivered with VMAT
      technique in oligometastatic patients affected by adrenal gland metastases.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase II, single arm, trial for testing efficacy of ablative high hypofractionated
      dose delivered with VMAT technique in oligometastatic patients with adrenal gland metastases.
      The potential advantages of this approach include the possibility to lead an increased local
      control in irradiated adrenal gland metastases. Other purpose of this study is to assess
      acute and late toxicity in terms of maintenance of endocrine mechanisms of hormonal
      production.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Control of local disease</measure>
    <time_frame>5 years</time_frame>
    <description>Evaluation of proportion of patients free from progression from starting radiotherapy according to CTCAE v4.03</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of acute and late complications</measure>
    <time_frame>5 years</time_frame>
    <description>Evaluation of early and late post treatment complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endocrine mechanisms of hormonal production</measure>
    <time_frame>5 years</time_frame>
    <description>Assessment acute and late toxicity in terms of maintenance of endocrine mechanisms of hormonal production according to CTCAE v4.03</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">37</enrollment>
  <condition>Adrenal Gland Metastases</condition>
  <arm_group>
    <arm_group_label>Stereotactic body radiation therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oligometastatic patients with adrenal gland metastases are treated with high dose of Stereotactic Body Radiation Therapy delivered with VMAT/Rapid Arc technique.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Stereotactic Body Radiation Therapy</intervention_name>
    <description>The schedule will be 3 fractions of 15 Gy up to a total dose of 45 Gy delivered every day with VMAT and Flattening filter-free (FFF) beams. Image-guided systems, including CBCT, will be used for all patients.</description>
    <arm_group_label>Stereotactic body radiation therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18years.

          -  WHO performance status ≤ 1 (ECOG - KPS).

          -  Histologically-proven of primary cancer disease

          -  Metastases at adrenal gland radiologically proven

          -  Written informed consent

        Exclusion Criteria:

          -  Prior radiation to the interested adrenal gland.

          -  Patients allergic to contrast used in CT scans or who cannot be premedicated for the
             use of contrast.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ciro Franzese, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Humanitas Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ciro Franzese, MD</last_name>
    <phone>+390282247454</phone>
    <email>ciro.franzese@cancercenter.humanitas.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Humanitas Research Hospital</name>
      <address>
        <city>Rozzano</city>
        <state>Milan</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ciro Franzese, MD</last_name>
      <phone>+390282247454</phone>
      <email>ciro.franzese@cancercenter.humanitas.it</email>
    </contact>
    <investigator>
      <last_name>Ciro Franzese, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lucia Di Brina, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Davide Franceschini, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 21, 2016</study_first_submitted>
  <study_first_submitted_qc>July 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 28, 2016</study_first_posted>
  <last_update_submitted>July 28, 2016</last_update_submitted>
  <last_update_submitted_qc>July 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Istituto Clinico Humanitas</investigator_affiliation>
    <investigator_full_name>Michele Tedeschi</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Adrenal Gland Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epinephrine</mesh_term>
    <mesh_term>Racepinephrine</mesh_term>
    <mesh_term>Epinephryl borate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

